

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 405/14, A61K 31/41</b>		<b>A1</b>	(11) International Publication Number: <b>WO 97/00255</b>
			(43) International Publication Date: 3 January 1997 (03.01.97)
<p>(21) International Application Number: PCT/US96/09242</p> <p>(22) International Filing Date: 17 June 1996 (17.06.96)</p> <p>(30) Priority Data:          60/000,305 19 June 1995 (19.06.95) US          08/596,852 5 February 1996 (05.02.96) US</p> <p>(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</p> <p>(72) Inventors: LOVEY, Raymond, G.; 65 Woodside Avenue, West Caldwell, NJ 07006 (US). GIRIJAVALLABHAN, Viyyoor, M.; 10 Mapplewood Drive, Parsippany, NJ 07054 (US). SAKSENA, Anil, K.; 53 Beverley Road, Upper Montclair, NJ 07043 (US). PIKE, Russell, E.; 31 Florence Street, R.D. #1, Stanhope, NJ 07874 (US). BENNET, Frank; 419 Draco Road, Piscataway, NJ 08854 (US).</p> <p>(74) Agents: BOXER, Matthew et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report.</p>	
<p>(54) Title: TETRAHYDROFURAN ANTIFUNGALS</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <p>(Ia)</p> </div> <div style="text-align: center;"> <p>(Ib)</p> </div> </div>			
<p>(57) Abstract</p> <p>A compound represented by a formula selected from the group consisting of (Ia) and (Ib), wherein X is independently selected from the group consisting of F and Cl; A is CH or N; R<sub>1</sub> is a straight or branched chain (C<sub>3</sub> to C<sub>8</sub>) alkyl group substituted by one or two hydroxy moieties, an ether or ester thereof (e.g., a polyether ester, a heterocyclic ester, an amino acid ester or phosphate ester thereof) or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

## TETRAHYDROFURAN ANTIFUNGALS

### BACKGROUND OF THE INVENTION

10

This invention relates to tetrahydrofuran antifungals, hydroxylic derivatives, esters, ethers and salts thereof, pharmaceutical compositions containing them, and methods of treating and/or preventing antifungal infections in hosts, including warm-blooded animals, especially humans with such


15 tetrahydrofuran antifungals.

20


There is a need for broad-spectrum antifungal agents having increased solubility and having favorable activity profile for treating systemic fungal infections, especially Aspergillus, Candida, Cryptococcus and other opportunistic fungal infections.

**SUMMARY OF INVENTION**

The present invention provides compounds represented by the following formulas



and




- 5                    wherein X is independently selected from the group consisting of  
F, Cl Br, and CF<sub>3</sub>;

A is N or CH;


R<sub>1</sub> is a straight or branched chain (C<sub>3</sub> to C<sub>8</sub>) alkyl group

- 10                   substituted by one or two hydroxy moieties or stereoisomers thereof or by one or  
two groups convertible in vivo into hydroxy moieties, or a pharmaceutically  
acceptable salt thereof.

In a preferred aspect of the present invention, there is provided  
compounds represented by formulas IIa and IIb




**and**




wherein X is independently selected from the group consisting of F, Cl, Br, and CF<sub>3</sub>;

wherein R<sub>2</sub> is H or (C<sub>1</sub>-C<sub>3</sub>) alkyl and R<sub>3</sub> is (C<sub>1</sub>-C<sub>3</sub>) alkyl substituted  
5 by one hydroxy moiety or by a group convertible in vivo into a hydroxy moiety  
and the carbon with the asterisk (\*) has the R or S absolute configuration; or a  
pharmaceutically acceptable salt thereof.




In another preferred aspect, the present invention provides a compound represented by formulas IIIa and IIIb




and



wherein R<sub>5</sub> is







an ester, carbonate, or urethane thereof or a pharmaceutically acceptable salt thereof.

- 5 Preferably the ester or ether is a group convertible in vivo into OH e.g. a polyether ester, phosphate ester, heterocyclic esters or an amino acid ester, or a pharmaceutically acceptable salt thereof.

In another aspect of the present invention there is provided a compound represented by the formulas IVa and IV b



and




wherein  $R_9 = -\overset{*}{\text{C}}\text{H}(\text{C}_2\text{H}_5)\text{CH}(\text{R}_6)\text{CH}_3$  or  $-\overset{*}{\text{C}}\text{H}(\text{CH}_3)\text{CH}(\text{R}_6)\text{CH}_3$




wherein  $R_6$  is OH, or a group convertible in vivo into OH, or a  
 5 pharmaceutically acceptable salt thereof.

Exemplary of the compounds of the invention are the following:


10









5




10



5


and



10

or a pharmaceutically acceptable salt thereof.


The most preferred compound of the invention is




or a pharmaceutically acceptable salt thereof; or an  $\alpha$ -amino acid ester thereof; or a pharmaceutically acceptable salt of an  $\alpha$ -amino acid ester thereof.

The hydroxy compound shown just above is preferred for oral use.

The invention further relates to amino acid esters of the type shown just below:



and



wherein X is independently selected from the group consisting of F, Cl, Br, and CF<sub>3</sub>;


A is N or CH;

R is H, CH<sub>3</sub>, or C<sub>2</sub>H<sub>5</sub>;

R' is H, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>;

AN<sup>-</sup> is an anion such as Cl<sup>-</sup> or C<sub>3</sub>H<sub>5</sub>O<sub>3</sub><sup>-</sup> ;

R<sup>n</sup> is H, CH<sub>3</sub>, CH<sub>2</sub>OR<sup>m</sup>, CH(OR<sup>m</sup>)CH<sub>3</sub>, CH<sub>2</sub>SR<sup>m</sup>,



5 CH<sub>2</sub>COO<sup>-</sup> M<sup>+</sup>, CH<sub>2</sub>CH<sub>2</sub>COO<sup>-</sup> M<sup>+</sup>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>3</sub><sup>+</sup> AN<sup>-</sup>



M<sup>+</sup> is a metal cation such as Na<sup>+</sup>; and

10 R<sup>m</sup> is H, phosphate ester, sulphate ester and proline ester.

An α-amino acid ester thereof which is shown just above is preferred for intravenous use.

15

### DETAILED DESCRIPTION OF THE INVENTION

The term "(C<sub>3</sub>-C<sub>8</sub>) alkyl group substituted by one or two hydroxy moieties", as used herein means straight and branched chain alkyl groups of three to eight carbons including but not limited to methyl, ethyl, n- and iso-propyl, n-, sec-, iso- and tert-butyl, n-, sec-, iso-, tert and neo-pentyl n-, sec-, iso-, tert- and neo-hexyl, n-, sec-, iso-, tert- and neo-heptyl, n-, sec-, iso-, tert- and neo-

octyl, substituted by one or two hydroxy moieties and includes R and S stereoisomers of such (C<sub>3</sub>-C<sub>8</sub>) alkyl groups.

The term "(C<sub>1</sub>-C<sub>3</sub>) alkyl substituted by one hydroxy moiety" means -CH<sub>2</sub>OH, -<sup>\*</sup>CH(OH)CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -<sup>\*</sup>CH(OH)C<sub>2</sub>H<sub>5</sub>,  
 5 -<sup>\*</sup>CH<sub>2</sub>CH(OH)CH<sub>3</sub>, and -(CH<sub>2</sub>)<sub>3</sub>-OH wherein the carbons with the asterisk(\*) have the R or S absolute configuration.

The term "hydroxy-substituted C<sub>4</sub> or C<sub>5</sub> alkyl group" means -<sup>\*</sup>CH(C<sub>2</sub>H<sub>5</sub>)<sup>\*</sup>CH(OH)CH<sub>3</sub>, -<sup>\*</sup>CH(C<sub>2</sub>H<sub>5</sub>)CH<sub>2</sub>CH<sub>2</sub>OH, -(CH<sub>2</sub>)<sub>2</sub>-<sup>\*</sup>CH(OH)C<sub>2</sub>H<sub>5</sub>,  
 -<sup>\*</sup>CH(CH<sub>3</sub>)<sup>\*</sup>CH(OH)CH<sub>3</sub>, -<sup>\*</sup>CH(CH<sub>3</sub>)<sup>\*</sup>CH(OH)CH<sub>3</sub> or -<sup>\*</sup>CH(C<sub>2</sub>H<sub>5</sub>)CH<sub>2</sub>OH  
 10 wherein each carbon with the asterisk (\*) has the R or S absolute configuration.

The term "MEM" means methoxyethoxymethyl.

The term "group convertible in vivo into OH" means a group transformable in vivo by e.g. hydrolysis and/or by an enzyme, e.g. an esterase into a hydroxyl group. Such groups include polyether esters, phosphate esters,  
 15 sulfate esters, heterocyclic esters, alkanoate esters, alkenoate esters, carbonate esters, amino acid esters, carbamate esters, and acid esters. Preferred groups convertible in vivo into a hydroxyl group are the polyether esters, phosphate esters and amino acid esters.

The term "ether" as it relates to protective groups in the syntheses  
 20 given herein, means (C<sub>1</sub>-C<sub>6</sub>) alkoxy or aryl (C<sub>1</sub>-C<sub>6</sub>) alkoxy which are conveniently made by the well known Williamson Synthesis of ethers. Typically suitable ether groups include methoxy and benzoxy.

The term "esters" means (a) polyether esters (b) phosphate esters (c) heterocyclic esters (d) alkanoate and alkenoate esters (e) amino-acid esters  
 25 (f) carboxylic acid esters (g) carbonic and carbamic acid esters and (h) sulfate esters.

The term "polyether esters" as used herein means those polyether esters represented by the formula

$$\text{—O—}\overset{\text{O}}{\underset{\text{||}}{\text{C}}}\text{—(CHR}_7\text{)}_s\text{—(OCHR}_7\text{CHR}_7\text{)}_t\text{—OR}_8$$

wherein



R<sub>7</sub> is a (C<sub>1</sub>-C<sub>6</sub>) straight or branched chain alkyl. Where more than one R<sub>7</sub> appear in a molecule, each R<sub>7</sub> may be the same or different from the others. "s" is an integer from 1 to 6, preferably s = 1 to 3 and more preferably s = 1; t is an integer from 1 to 200;

- 5 R<sub>8</sub> is R<sub>7</sub> or  $\text{---}(\text{CHR}_7)_s\text{---CO}_2\text{R}_7$ ; preferably R<sub>8</sub> is CH<sub>3</sub> or C<sub>2</sub>H<sub>5</sub> or  $\text{---CH}_2\text{CO}_2\text{H}$  or  $\text{---CH}_2\text{CO}_2\text{CH}_3$ . Typically suitable polyether esters


include  $\text{---COCH}_2\text{O}(\text{CH}_2\text{CH}_2\text{O})_1\text{CH}_3$ ;  $\text{---COCH}_2\text{O}(\text{CH}_2\text{CH}_2\text{O})_2\text{CH}_3$ , and

- 10  $\text{---COCH}_2\text{O}(\text{CH}_2\text{CH}_2\text{O})_3\text{CH}_3$ .


The term "phosphate esters" as used herein means those phosphate acids esters represented by the formula



defined herein above and preferably is H, and where more than one R<sub>7</sub> appears in a molecule, each R<sub>7</sub> may be the same or different from the others; n and f are independently an integer from 0 to 6, m is 0 or 1 and Q is H, CH<sub>2</sub>Ar or




- 20 and wherein Ar is phenyl, phenyl substituted by halo, especially chloro and fluoro, or by nitro, cyano and trihalomethyl especially trifluoromethyl.



wherein  $m = n = 1$  to  $4$ ; or  $\text{—O—C(=O)—CH(CH}_3\text{)—O—P(=O)(OH)}_2$  and pharmaceutically acceptable salts thereof.


- 5 The term "heterocyclic ester" as used herein means heterocyclic esters



represented by the formula

wherein  $R_7$  is as defined herein above,  $w$  is an integer of from  $1$  to  $5$  preferably  $w$  is  $1$  to  $3$ ;  $q$  and  $q'$  are independently  $1$  to  $4$ , and  $q + q'$  are preferably equal to  $2, 3, 4$ , or  $5$ , and  $Y$  is  $\text{CHR}_7, \text{—O—}, \text{NH}, \text{NR}_7, \text{S}, \text{SO}$  or  $\text{SO}_2$

- 10 Typically suitable heterocyclic esters include



The term "alkanoate and alkenoate esters" as used herein means straight or branched chain alkanoate or alkenoate groups optionally substituted by a hydroxy or ether moiety or mixtures of such alkanoates or alkenoates.


- 15 Preferred alkanoate esters include acetate to decanoate, especially acetate to butanoate. Preferred hydroxy substituted alkanoate ester include  $\text{C}_1$

to C<sub>8</sub> alkanooate substituted one hydroxy moiety or one C<sub>1</sub>-C<sub>6</sub> alkoxy group,

especially  $\text{—O—C(=O)—CH}_2\text{OCH}_3$ ,  $\text{—O—C(=O)—CH}_2\text{OH}$  and  $\text{—O—C(=O)—CH(OH)CH}_3$ .



Preferred alkenoate esters are the C<sub>10</sub>-C<sub>20</sub> alkenoates and include C<sub>14</sub> to C<sub>18</sub> alkenoates, such as cis-7-hexadecenoate.

- 5        The term "amino acid ester" as used herein includes α-aminoalkanoyloxy, natural i.e., (L)-α-amino acid ester groups, e.g. the ester of glycine, peptide esters thereof, unnatural α-amino acid ester groups such as O-CO-CH(NH<sub>2</sub>)(CH<sub>2</sub>)<sub>3</sub>CO<sub>2</sub>H, OCOCH(NH<sub>2</sub>)(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, OCOCH(NH<sub>2</sub>)(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>




and

- 10       α-amino alkanooates represented by the formula -OCOCH (NR<sub>20</sub>R<sub>21</sub>)R<sub>22</sub> wherein R<sub>20</sub> and R<sub>21</sub> are independently hydrogen or (C<sub>1</sub>-C<sub>8</sub>) straight or branched chain alkyl groups or R<sub>20</sub> and R<sub>21</sub> together with N form a 4, 5 or 6 membered ring optionally substituted with NR<sub>21</sub>, -O- or -S- and R<sub>22</sub> is H, CH<sub>3</sub>, CH<sub>2</sub>OH, CH(OH)CH<sub>3</sub>, CH<sub>2</sub>SH,



15

CH<sub>2</sub>CONH<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>CONH<sub>2</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, CH(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, (CH<sub>2</sub>)<sub>2</sub>SCH<sub>3</sub>, CH<sub>2</sub>CO<sub>2</sub>H, (CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>H, (CH<sub>2</sub>)<sub>4</sub>NH<sub>2</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>,



and pharmaceutically acceptable acid addition salts

thereof, or (C<sub>1</sub>-C<sub>8</sub>) straight and branched chain alkyl groups optionally

- 20       substituted by hydroxyl or NR<sub>20</sub>R<sub>21</sub>. Preferred amino acid acids are the natural α amino acid groups, dipeptides and α-amino alkanooates wherein R<sub>20</sub> and R<sub>21</sub>



are each CH<sub>3</sub>. The most preferred amino acid esters are those derived from alanine, phenylalanine, glycine, leucine, isoleucine and valine.

The term "carboxylic acid ester" as used herein means those acid esters


represented by the formula 
$$\text{—O—C(=O)—(CR}_7\text{R}_7\text{)}_k\text{—C(=O)—OH}$$
 wherein each R<sub>7</sub> is as

5 defined herein above, and where more than one R<sub>7</sub> appears in a molecule, each R<sub>7</sub> may be the same or different from the others, and k is an integer of from 1 to 8. Typically suitable acid esters include oxalic, malonic, succinic, glutaric and adipic acids as well as branched chain diacids such as



10 Preferred salts are HCl and lactic acid.

The term "carbonic and carbamic acid esters" means



wherein n is 1, 2 or 3;

R<sub>10</sub> is OH, NHR or a salt thereof; and

15 R is H, CH<sub>3</sub> or C<sub>2</sub>H<sub>5</sub>.


The term "LG" means a leaving group, and unless otherwise noted may be Cl, Br, I, OSO<sub>2</sub>CH<sub>3</sub>, OSO<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, OSO<sub>2</sub>(C<sub>6</sub>H<sub>4</sub>)CH<sub>3</sub>, OSO<sub>2</sub>(C<sub>6</sub>H<sub>4</sub>)Cl, OSO<sub>2</sub>(C<sub>6</sub>H<sub>4</sub>)Br, OSO<sub>2</sub>(C<sub>6</sub>H<sub>4</sub>)NO<sub>2</sub>, OSO<sub>2</sub>(CF<sub>2</sub>)<sub>p</sub>F where p is 1 to 4.

20 The term "Hal" means halogens, and unless otherwise noted may be Cl, Br and I.

The term "PG" means a protecting group, and unless otherwise noted may be CH<sub>2</sub>Ph (benzyl), CH<sub>2</sub>OCH<sub>3</sub> (MOM), CH<sub>2</sub>OCH<sub>2</sub>Ph (BOM), CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> (MEM), CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>Si(CH<sub>3</sub>)<sub>3</sub> (SEM)

Compounds of the invention exhibited the following in vitro antifungal activity in EMEM against 11 strains of *C. albicans* and *tropicalis*: geometric mean MICs in the range of  $\geq 0.01$  to  $\geq 0.10$  (mcg/ml).


5 The most preferred compound of the invention,



exhibited the following in vitro antifungal activity in EMEM against 11 strains of *C. albicans* and *tropicalis*: geometric mean MICs of  $\geq 0.01$  (mcg/ml).


10 Compounds of the invention also exhibited in vivo antifungal activity.

The more preferred esters listed hereinabove are water soluble and readily convertible in vivo to the corresponding alcohols e.g. R<sub>5</sub> is




15

Compounds of the present invention represented by formula Ia and Ib can exist in the "cis" isomeric form. With reference to formula Ia, for example,




5

"cis" means that the



moiety and the




moiety


10 are on the same side of the of the tetrahydrofuran ring.

The same meaning for the term "cis" attaches to formulas Ib, IIa, IIb, IIIa, IIIb, IVa and IVb and the structures of the final products of the invention.

By relative stereochemistry, it is understood that the compound  
15 just below:





can either have the stereochemistry shown or be the enantiomer thereof, that is



- Unless otherwise indicated, structures of other compounds
- 5 throughout this application which show the cis stereochemistry about the tetrahydrofuran ring are to be understood as encompassing the compound shown or the enantiomer thereof.

Certain compounds of the invention differ from other compounds of the invention with respect to the points of attachment of the various moieties to the

10 tetrahydrofuran ring. Ring numbering for certain positions on the tetrahydrofuran ring is given for formulas Ia and Ib just below.




From the formulas just above, it can be seen that formula Ia compounds of the invention are known as 2,2,5 compounds, that formula Ib compounds of the invention are known as 2,4,4 compounds.

## 5 GENERAL SYNTHETIC PREPARATIONS

Compounds of the invention may be prepared according to the reaction schemes shown just below. The starting materials in these reaction schemes are either known or can be prepared according to known methods.


### SCHEME 1: 2,4,4-Tetrahydrofuran Compounds,




**Reagents:** (a) NaOEt, EtOH, allyl bromide ; (b) LiAlH<sub>4</sub>, EtOEt ; (c) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub> ; (d) chromatography ; (e) Dihydropyran, H<sup>+</sup> ; (f) YO<sup>-</sup> ; (g) H<sup>+</sup> ; (h) Mesylation ; (i) Azole anion (Z=N,CH), DMF, heat ; (j) Chiralcell chromatography, using a Daicel OD, Chiralcell column.

The reactions shown in the scheme 1 just above can be carried out in a manner analogous to that set forth in U. S. Patent 5,039,676, column 23, line 42 through column 24, line 7. U. S. Patent 5,039,676 is hereby incorporated by reference.

5

**SCHEME 2: 2,4,4-Tetrahydrofuran Compounds,**


## SCHEME 2: contd.



Reagents: (a) NaOH, n-BuOH; (b) *p*-Cl-C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMSO; (c) H<sub>2</sub>, Pt-C; (d) C<sub>6</sub>H<sub>5</sub>OCOCl, pyridine, CH<sub>2</sub>Cl<sub>2</sub>.

The reactions shown in the scheme 2 just above can be carried out in a manner analogous to that set forth in scheme V, page 28 and scheme VI, page 29 of commonly assigned copending U. S. Ser. No. 08/460,752, filed June 2, 1995. U. S. Ser. No. 08/460,752, filed June 2, 1995 is hereby incorporated by reference.


Compounds of formula **14** just below:



can be prepared in a manner analagous to that set forth in scheme VI, page 28 of commonly assigned copending U. S. Ser. No. 08/460,752, filed June 2,

5 1995.

**Scheme 3**




**Reagents:** (h) allyl magnesium bromide, CuI, THF; (i) *m*-chloroperbenzoic acid; (j) Et<sub>3</sub>N, toluene, Δ; (k) chromatography; (l) tosyl chloride, Et<sub>3</sub>N.

Compounds of formula **19** can be prepared as shown in scheme 3 above by treating a suitably substituted chiral epoxide, e.g. **14**, with an allyl magnesium halide in an appropriate solvent, e.g. THF, in the presence of a catalyst, e.g. CuI, at a suitable temperature, e.g. -70°C to 0°C, to produce an hydroxylic olefin, e.g. **16**. The hydroxylic olefin so produced can be treated with an appropriate oxidizing agent, e.g. *m*-chloroperbenzoic acid, in a suitable solvent, e.g. CH<sub>2</sub>Cl<sub>2</sub>, at 0°C to 25°C to produce an hydroxylic epoxide, e.g. **17**. The hydroxylic epoxide so produced can be treated with a tertiary amine base, e.g.




Et<sub>3</sub>N, or NaH in a suitable inert solvent, e.g. toluene, at an elevated temperature, e.g. 90°C to 110°C, to produce an hydroxylic tetrahydrofuran, e.g. 18. The hydroxylic tetrahydrofuran so produced can be treated with an alkyl- or arylsulfonyl halide, e.g. toluenesulfonyl chloride, in the presence of an organic  
5 amine base, e.g. Et<sub>3</sub>N or N,N-dimethylaminopyridine, in a suitable solvent to produce the corresponding sulfonate, e.g. 19.

Scheme 4




(cont. next page)




**Reagents:** (a) NaH, DMF; (b) NaOH, n-BuOH; (c) *p*-Cl-C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMSO; (d) H<sub>2</sub>, Pt-C; (e) C<sub>6</sub>H<sub>5</sub>OCOCl, pyridine, CH<sub>2</sub>Cl<sub>2</sub>; (f) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, H<sub>2</sub>O, dioxane; (g) formamidine acetate, DMF, 80°C; (h) according to Scheme II, pg 25 and Examples 19 and 20, of U.S. Ser. No. 08/460,752, filed June 2, 1995

The compounds of formula Ia can be prepared from compounds of formula 19 by the reactions shown in scheme 4 above carried out in a manner analogous to that set forth in scheme II, page 24, of commonly assigned  
 5 copending U.S. Ser. No. 08/460,572, filed June 2, 1995.

If, in the above reaction scheme 3, the S epoxide is




used:  
 , then the corresponding final product of different stereochemistry will be obtained from scheme 4. For example, using such a starting epoxide, the following product was obtained:



10


As can be seen from the above formulas and from other formulas in the specification, S or R is sometimes used to indicate the stereochemistry of a particular chiral center of a molecule.

## SCHEME 5




- 5 The reactions shown in the scheme 5 just above can be carried out in a manner analogous to that set forth in scheme 4, page 27 of commonly assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995. As used herein, SEM means  $\text{CH}_2\text{OCH}_2\text{CH}_2\text{SiMe}_3$ .

## SCHEME 6



The reactions shown in the scheme 6 just above can be carried out in a  
 5 manner analogous to that set forth in scheme V, page 28 of commonly  
 assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.



**Scheme 7**

(a) pyrrolidine, r.t., 24 h; (b)  $R_7-X$ , NaH, DMF; (c) RED-AL, toluene,  $-20^\circ$ ;  
 (d)  $H_2NNHCHO$ , MeOH; (e)  $R'_7MgBr$ ,  $Et_2O$ ,  $-10^\circ C$  to r.t., 24 h; (f) toluene,  
 DBU,  $80^\circ C$ , 6 Hours;  $100^\circ C$ , 16 hours; (g)  $H_2$ , Pd, HCOOH,  $80^\circ C$ .

wherein  $R_4$  is  $\text{CH}_2\text{Ph}$ ,  $\text{CH}_2\text{CH}_3$  (MOM),  $\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$  (MEM),  $\text{CH}_2\text{OCH}_2\text{CH}_2\text{SiMe}_3$  (SEM), or  $\text{CH}_2\text{OCH}_2\text{Ph}$  (BOM).


The reactions shown in the scheme 7 just above can be carried out in a manner analogous to that set forth in scheme VI, page 29 of commonly assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995. LG is a leaving group such as chlorine.

### Scheme 8




The reactions shown in the scheme 8 just above can be carried out in a manner analogous to that set forth in scheme VII, page 30 of commonly assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.






The reactions shown in the scheme 8a just above can be carried out in a manner analogous to that set forth in scheme VIIIA, page 31 of commonly assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.

Scheme 9


5 Hal=Br or Cl.

The reactions shown in scheme 9, above can be carried out in a manner analogous to that set forth in VIIB, page 32 of commonly assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.

In the table just above, the compound la, when R<sub>1</sub> is  $\begin{array}{c} \text{R} \text{---} \text{Me} \\ \diagup \quad \diagdown \\ \text{S} \\ \diagdown \quad \diagup \\ \text{Me} \end{array} \text{OH}$ , is  
 10 also referred to as compound 50. Similarly, two labels are also used for compound 52


**Scheme 10**

The reactions shown in scheme 10 just above can be carried out in a  
 5 manner analogous to that set forth in scheme VIIC, of page 34 of commonly  
 assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.

**Scheme 11**

The reactions shown in the scheme 11, just above can be carried out in a manner analogous to that set forth in scheme IX, page 36 of commonly assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.

Scheme 12



**Reagents:** (a)  $\text{R}'\text{-CH(NH.PG)-COOH}$ , DCCD, DMAP,  $\text{CH}_2\text{Cl}_2$ ; (b)  $\text{HCl}$  in dioxane

Where  $\text{R}' = \text{H}, \text{CH}_3, \text{CH}_2\text{OH}, \text{CH}(\text{OH})\text{CH}_3, \text{CH}_2\text{SH}, \text{CH}_2\text{CONH}_2,$

$\text{CH}_2\text{CH}_2\text{CONH}_2, \text{CH}(\text{CH}_3)_2, \text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3, \text{CH}_2\text{CH}_2\text{SMe}, \text{CH}_2\text{COO}^-,$


$\text{CH}_2\text{CH}_2\text{COO}^-, (\text{CH}_2)_4\text{NH}_3^+, \text{H}_2\text{C}-\text{C}_6\text{H}_4, \text{H}_2\text{C}-\text{C}_6\text{H}_4\text{-OR}_3, \text{H}_2\text{C}-\text{C}_8\text{H}_7\text{N},$

$\text{H}_2\text{C}-\text{C}_5\text{H}_4\text{N}^+, \text{H}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{C}(\text{NH}_3^+)=\text{NH}$ ;  $\text{R}_3 = \text{H}, \text{Phosphate ester}, \text{Sulphate ester},$   
 $\text{PG} = \text{CH}_2\text{Ph}$


The reactions shown in the scheme 12, just above can be carried out in  
 5 a manner analogous to that set forth in scheme X, page 37 of commonly  
 assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.

Using an appropriate amino acid and an appropriate compound in place  
 of compound 62, the reaction scheme 12, shown just above, can be carried out


by one skilled in the art so as to arrive at any amino acid ester salts of the formulas

AN<sup>-</sup>

and


AN<sup>-</sup>

Scheme 13



Reagents: (a) 2,2,2-trichloroethanol; (b) silver dibenzyl phosphate; (c) Zn, HOAc-THF; (d)  $\text{SOCl}_2$ ; (e) 42; (f)  $\text{H}_2$ , 10% Pd-C; (g) 2eq. N-methyl glucamine.


As used in the Schemes 13 and 14 AR is



5

The reactions shown in the scheme 13, just above can be carried out in a manner analogous to that set forth in scheme XIA, page 38 of commonly assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.

### Scheme 14



**Reagents:** (a) 2,2,2-trichloroethanol, DCCD, DMAP; (b) N-bromosuccinimide; (c) silver dibenzyl phosphate; (d) Zn, HOAc-THF; (e) compound 42  
DCCD, DMAP; (f) H<sub>2</sub>, 10% Pd-C; (g) 2eq. N- methyl glucamine

5                   The reactions shown in the scheme 14, just above can be carried out in a manner analogous to that set forth in scheme XIB, page 39 of commonly assigned copending U.S. Ser. No. 08/460,572, filed June 2, 1995.


The compounds of this invention are prepared in accordance with Schemes hereinabove and the following Examples using commercially available starting materials, or using starting materials which can be prepared by known methods.

EXAMPLE OF THE PREPARATION OF [(R)-CIS]-4-[4-[4-[4-[(5-(2,4-  
15 DIFLUOROPHENYL)-TETRAHYDRO-5-[(1H-1,2,4-TRIAZOL-1-YL)METHYL]-2-



FURANYLMETHOXY]PHENYL}-1-PIPERAZINYL]PHENYL}-2-(1(S)-ETHYL-  
2(S)-HYDROXYPROPYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE (42)

which has the structural formula



5

#### COMPOUND 16. $X=F$

Add copper(I) iodide (50 mg) to a solution of 15,  $X=F$  (16 g) in anhydrous THF (300 mL). Stir the mixture and cool it to  $-70^{\circ}\text{C}$ , and then slowly  
10 add a solution of 2.0 M allylmagnesium chloride in THF (52 mL). Allow the mixture to warm to r.t. and stir for an additional 3 hr. Quench the reaction with 1:1 saturated brine-10% aq.  $\text{KH}_2\text{PO}_4$ , extract with EtOAc, dry the extract over anhydrous  $\text{Na}_2\text{SO}_4$ , and filter the mixture. Evaporate the solvent and chromatograph the residue on silica gel with acetone-hexane to obtain the title  
15 compound 16,  $X=F$  (9.7 g),  $M^+$  280.3.

#### COMPOUND 17. $X=F$

A solution of the above olefin 16,  $X=F$  (11.2 g) in  $\text{CH}_2\text{Cl}_2$  (250 mL) at  $-10^{\circ}\text{C}$  is slowly treated with 85% purity *m*-chloroperbenzoic acid (9.0 g), and the  
20 mixture is then stirred at r.t. for 24 hr. The reaction mixture is washed with cold 5% aq. NaOH, then water, then saturated brine. The solution is dried over anhydrous  $\text{MgSO}_4$ , filtered, and the filtrate evaporated to leave the title compound 17,  $X=F$  (11.8 g), which is used without further purification.

25

#### COMPOUND 18. $X=F$

- Stir and heat at 80°C a solution of the epoxide **17**, **X=F** from above (10 g), toluene (125 mL), and Et<sub>3</sub>N (6.0 mL) for 2 hr. Suction-filter the hot mixture through a pad of silica gel and wash the pad with EtOAc. Evaporate the combined organics to leave a residue of a mixture of *cis*- and *trans*- alcohols.
- 5 The residue is chromatographed on silica gel with MeOH-CH<sub>2</sub>Cl<sub>2</sub> to give the title *cis*-compound **18**, **X=F** as the first of the isomers to elute.

COMPOUND **31** (**19**, **X=F**)

- Stir a solution of the alcohol from above (12.4 g), Et<sub>3</sub>N (5.9 mL), and
- 10 DMAP (0.5 g) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL). Add tosyl chloride (8.2 g) and stir for 4 hours. Wash the mixture with cold aqueous 5% KH<sub>2</sub>PO<sub>4</sub>, and dry the organic layer over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Filter the mixture, evaporate the filtrate to a residue, and crystallize the residue from EtOAc-(i-Pr)<sub>2</sub>O to obtain the tosylate **31** (4.2 g), mp 150-151°C.

15

COMPOUND **32**


- Stir a mixture of compound **30** (1.5 g), scheme 5, and Cs<sub>2</sub>CO<sub>3</sub> (1.25 g) in DMF (50 mL) for 0.75 hours. Add the tosylate **31** from above (1.4 g) and stir at 80°C for 18 hours. Pour the mixture into aqueous 5% KH<sub>2</sub>PO<sub>4</sub> and extract with
- 20 EtOAc. Evaporate the extract and chromatograph the residue on silica gel to obtain compound **32** (1.4 g).

COMPOUND **33**

- Stir a mixture of the compound **32** from above (1.4 g) in 1,4-dioxane (8
- 25 mL) and 12N HCl (15mL) at 90°C for 18 hours. Pour the mixture in water, add NaHCO<sub>3</sub> until the pH=4, and extract with EtOAc. Evaporate the extract and boil the residue in CH<sub>3</sub>CN. Allow to cool and filter to leave compound **33** (0.7 g), FAB mass spectrum: M<sup>+</sup> 615.

COMPOUND 34,  $R_1 = (S,S)\text{-CH}(\text{CH}_3\text{CH}_2)[(\text{CH}(\text{OCH}_2\text{OCH}_2\text{Ph})\text{CH}_3]$

Stir a mixture of compound 33 (0.7 g) and  $\text{Cs}_2\text{CO}_3$  (0.4 g) in DMF (20 mL) for 0.75 hours.



5 Add compound 80 (0.8 g),

a compound which can be prepared by known means and stir at  $80^\circ\text{C}$  for 18 hours. Pour the mixture into aqueous 5%  $\text{KH}_2\text{PO}_4$ , extract with EtOAc, evaporate the extract, and chromatograph the residue on silica gel to obtain compound 34 wherein  $R_1 = (S,S)\text{-CH}(\text{CH}_3\text{CH}_2)[(\text{CH}(\text{OCH}_2\text{OCH}_2\text{Ph})\text{CH}_3]$  (0.5 g), FAB mass spectrum:  $\text{M}^+$  821.

#### COMPOUND 42

Stir a solution of the compound from above (0.5 g) in 1:1 MeOH-6N HCl (20 mL) for 5 hours. Add  $\text{NaHCO}_3$  until the  $\text{pH} > 4$ . Extract with EtOAc, 15 evaporate the extract, boil the residue in  $\text{Et}_2\text{O}$ , and filter to leave compound 42 (0.35 g), mp  $165\text{-}167^\circ\text{C}$ ;  $[\alpha]_D +5.5^\circ$  ( $c=0.5$ ,  $\text{CH}_2\text{Cl}_2$ ).

The mass spectral data presented herein as  $\text{M}^+$  are parent ions which were determined by Fast Atom Bombardment (FAB) technique and 20 represent the  $[\text{M}+\text{H}^+]$ , i.e. {molecular ion+1} peaks.

Schemes 1-7 set forth the preferred processes to prepare the alcohol compounds of this invention.

As used in scheme 8 and elsewhere in this specification, the base 4-(N,N-dimethylamino)pyridine is referred to as "DMAP" and dicyclohexylcarbodiimide is referred to as DCCD.

5 The alkanoate and alkenoate esters of compounds of formula Ia and Ib are conveniently prepared by standard synthetic techniques, for example, by reaction of the anhydride or acid halide of the alkanoic acid or alkenoic acid in the presence of base e.g, pyridine.

The carbonic and carbamic esters of formulas 1a and 1b are conveniently prepared by standard synthetic techniques, for example, by the  
10 reaction of phosgene in the presence of a controlled amount of base, for example, pyridine, followed by reaction with an alcohol or amine in the presence of a base, for example, Et<sub>3</sub>N and DMAP.

The sulfate esters may be prepared by reaction of the alcohol compounds of formulas I to IV with sulfur trioxide in the presence of excess  
15 pyridine at temperatures of 70°–90°C for at least 2 hours in accordance with the procedure of R.M. Moriarty et. al. Tetrahedron Letters, Vol. 35, No. 44, p 8103-8106 (1994).

Compounds represented by formula I exhibit broad spectrum antifungal activity, in conventional antifungal screening tests, against human  
20 and animal pathogens, such as the following: *Aspergillus*, *Blastomyces*, *Candida*, *Cryptococcus*, *Coccidioides*, *Epidermophyton*, *Fonsecaea*, *Fusarium*, *Mucor*, *Saccharomyces*, *Torulopsis*, *Trichophyton*, *Trichosporon*, *Sporothrix* and *Pneumocystis*.

The antifungal compounds of formula I and pharmaceutical  
25 compositions of this invention are expected to exhibit anti-allergic, anti-inflammatory and immunomodulating activities, broad spectrum antiinfective activity, e.g., antibacterial, anti-protozoal and antihelminthic activities.

The present invention also provides a composition for treating or preventing fungal infections comprising an antifungally effective amount of a

compound represented by formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent therefor.

The pharmaceutical compositions of the present invention may also contain a fungicidally effective amount of other antifungal compounds such as cell wall active compound. The term "cell wall active compound", as used herein, means any compound that interferes with the fungal cell wall and includes, but is not limited to, compounds such as papulacandins, echinocandins, and aculeacins as well as fungal cell wall inhibitors such as nikkomycins, e.g., nikkomycin K and others which are described in USP 5,006,513 which is hereby incorporated by reference.

The pharmaceutically acceptable salts of the compounds of the present invention include pharmaceutically acceptable acid and base addition salts.

The preferred pharmaceutically acceptable acid addition salts are nontoxic acid addition salts formed by adding to the compounds of the present invention about a calculated amount of a mineral acid, such as HCl, HBr, H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub> or H<sub>3</sub>PO<sub>4</sub>, or of an organic acid, such as an alkyl or arylsulfonic acid such as maleic, lactic, methanesulfonic, isithionic, para- toluenesulfonic, naphthylsulfonic and the like.

The pharmaceutically acceptable bases found suitable for use in the present invention are those which form pharmaceutically acceptable salts of the acidic pharmaceutically acceptable esters of the antifungal compounds of formulas Ia and b, IIa and b, IIIa and b or IVa and b and include suitable organic and inorganic bases. Suitable organic bases include primary, secondary and tertiary alkyl amines, alkanolamines, aromatic amines, alkylaromatic amines and cyclic amines. Exemplary organic amines include the pharmaceutically acceptable bases selected from chlorprocaine, procaine, piperazine, glucamine, N-methylglucamine, N-N-dimethyl glucamine, ethylenediamine, diethanolamine, diisopropylamine, diethylamine, N-

benzylenediamine, diethanolamine, diisopropylamine, diethylamine, N-benzyl-2-phenylethylamine, N-n'dibenzylethylenediamine, choline, triethylamine ("ET<sub>3</sub>N"), tris(hydroxymethyl)aminomethane, or D-glucosamine. The preferred organic bases include N-methyl glucamine ("NMG"), diethanolamine, and  
5 tris(hydroxymethyl) aminomethane ("TRIS"). Use of two equivalents of NMG in this invention is more preferred. The suitable inorganic bases also include alkali metal hydroxides such as sodium hydroxide.

The pharmaceutical compositions of the present invention may be adapted for any mode of administration e.g., for oral, parenteral, e.g., SC, IM. IV  
10 and IP, topical or vaginal administration or by inhalation (orally or intranasally) Such compositions are formulated by combining the compound of formula Ia or Ib or an equivalent amount of a pharmaceutically acceptable salt of compound Ia or Ib with an suitable, inert, pharmaceutically acceptable carrier or diluent.

Examples of suitable compositions include solid or liquid  
15 compositions for oral administration such as tablets, capsules, pills, powders, granules, solutions, suppositories, troches, lozenges, suspensions or emulsions. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it can also be an encapsulating material.  
20 In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compound. In the tablet, the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

Topical dosage forms may be prepared according to procedures  
25 well known in the art, and may contain a variety of ingredients, excipients and additives. The formulations for topical use include ointments, creams, lotions, powders, aerosols, pessaries and sprays.

For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredients

are dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Liquid form preparations include solutions, suspensions and emulsions. Liquid form preparations include, for example, water or water-propylene glycol solutions for parenteral injection. Liquid preparations can also be formulated in solution with an appropriate amount of a hydroxypropyl  $\alpha$ -  $\beta$  or  $\gamma$ -cyclodextrin having 2 to 11 hydroxypropyl groups per molecule of cyclodextrin, polyethylene glycol, e.g., PEG-200 or propylene glycol, which solutions may also contain water. Aqueous solutions suitable for oral use can be prepared by adding the active component in water and adding suitable colorants, flavors, stabilizing, sweetening, solubilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the active component in finely divided form in water. A particularly preferred aqueous pharmaceutical composition may be prepared from the compounds of formulas I to IV together with hydroxypropyl- $\beta$ -cyclodextrin in water. The use of derivatives of  $\alpha$ -,  $\beta$ - and  $\gamma$ -cyclodextrins, for example, hydroxypropyl- $\beta$ -cyclodextrin are disclosed by N. Bodor USP 4,983,586, Pitha USP 4,727,064 and Janssen Pharmaceutical International Patent Application No. PCT/EP 84/00417.

The pharmaceutical compositions of the present invention may be prepared by admixing the pharmaceutically acceptable carrier, e.g., a hydroxypropyl- $\beta$ -cyclodextrin in water, and adding thereto an antifungally effective amount of a drug of the present invention. The solution so formed is filtered, and optionally, the water may be removed by well known methods, e.g., rotatory evaporation or lyophilization. The formation of the solution may take place at a temperature of about 15° to 35°C. The water is normally sterilized water and may also contain pharmaceutically acceptable salts and buffers, e.g., phosphate or citrate as well as preservatives. The molar ratio of the antifungal

compound of formula I to hydroxypropyl- $\beta$ -cyclodextrin is about 1:1 to 1:80, preferably 1:1 to 1:2. Normally the hydroxypropyl- $\beta$ -cyclodextrin is present in molar excess.

Also included are solid form preparations which are intended to be converted, shortly before use, into liquid form preparations for either oral or parenteral administration. The solid form preparations intended to be converted to liquid form may contain, in addition, to the active materials, such as compounds of this invention, and optionally a cell wall active compound, especially a fungal cell wall inhibitor, e.g., a nikkomycin, flavorants, colorants, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents and the like. The solvent utilized for preparing the liquid form preparations may be water, isotonic water, ethanol, glycerin, polyethylene glycols, propylene glycol, and the like, as well as mixtures thereof.

Parenteral forms to be injected intravenously, intramuscularly, or subcutaneously are usually in the form of a sterile solution, and may contain salts or glucose to make the solution isotonic.

The topical dosage for humans for antifungal use in the form of a pharmaceutical formulation comprising a compound of formula I (usually in the concentration in the range from about 0.1% to about 20% preferably from about 0.5% to about 10% by weight) together with a non-toxic, pharmaceutically acceptable topical carrier, is applied daily to the affected skin until the condition has improved.

In general, the oral dosage for humans for antifungal use ranges from about 1 mg per kilogram of body weight to about 30 mg per kilogram of body weight per day, in single or divided doses, with about 1 mg per kilogram of body weight to about 20 mg per kilogram of body weight per day being preferred and the dose of about 1 mg per kilogram of body weight to about 10 mg per kilogram of body weight per day being most preferred.




In general, the parenteral dosage for humans for antifungal use ranges from about 0.25 mg per kilogram of body weight per day to about 20 mg kilogram of body weight per day, in single or divided doses, with about 0.5 to about 10 mg per kilogram of body weight per day being preferred.


- 5           The exact amount, frequency and period of administration of the compounds of the present invention for antifungal use will vary, of course, depending upon the sex, age and medical condition of the patient as well as the severity of the infection as determined by the attending clinician.

**What Is Claimed Is:**

1. A compound represented by a formula selected from the  
 5 group consisting of



and



- wherein X is independently selected from the group consisting of F  
 10 Cl, Br, and CF<sub>3</sub>;

R<sub>1</sub> is a straight or branched chain (C<sub>3</sub> to C<sub>8</sub>) alkyl group  
 substituted by one or two hydroxy moieties, and esters thereof;


A is N or CH;

or a pharmaceutically acceptable salt thereof.


15

2. A compound of claim 1 wherein R<sub>1</sub> is a straight or branched  
 chain (C<sub>4</sub>-C<sub>5</sub>) alkyl group substituted by at least one hydroxy moiety.

3. A compound of claim 1 represented by a formula selected from the group consisting of



and



5


wherein X is independently selected from the group consisting of F, Cl Br, and CF<sub>3</sub>;

10                    wherein R<sub>2</sub> is H or (C<sub>1</sub>-C<sub>3</sub>) alkyl and R<sub>3</sub> is (C<sub>1</sub>-C<sub>3</sub>) alkyl substituted by one hydroxy moiety and the carbon with the asterisk (\*) has the R or S absolute configuration;

an ester thereof or a pharmaceutically acceptable salt thereof.

15                    4. A compound of claim 3 wherein R<sub>2</sub> or R<sub>3</sub> is (C<sub>1</sub>-C<sub>2</sub>)alkyl and each X is F.

5. A compound of claim 1 wherein  $R_1$  is a hydroxy-substituted  $C_4$ - or  $C_5$ -alkyl group selected from:




5


wherein  $R_4$  is OH or an ester thereof and the carbons with the asterisk(\*) have the R or S absolute configuration or a pharmaceutically acceptable salt thereof.

10


6. A compound of claim 1 represented by a formula selected from the group consisting of



and





wherein R<sub>5</sub> is





or an ester thereof or a pharmaceutically acceptable salt thereof.



7. A compound according to claim 1 selected from the group consisting of




5



10




5




10

and




or a pharmaceutically acceptable salt thereof.

- 5                      8. A compound of claim 1 represented by a formula selected from the group consisting of



and




10

wherein  $R_9 = \text{---}\overset{*}{\text{C}}\text{H}(\text{C}_2\text{H}_5)\text{CH}(\text{R}_6)\text{CH}_3$  or  $\text{---}\overset{*}{\text{C}}\text{H}(\text{CH}_3)\text{CH}(\text{R}_6)\text{CH}_3$



wherein  $R_6$  is OH, or an ester thereof or a pharmaceutically acceptable salt thereof.




9. A compound according to claim 1 selected from the group consisting of




5



10




and



or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 1 of the formula



5


or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition for treating or preventing fungal infection comprising an antifungally effective amount of a compound of claim 1 together with a pharmaceutically acceptable carrier therefor.


12. A method of treating and/or preventing fungal infections in a mammal afflicted with same which comprises administering an antifungally effective amount of a compound of claim 1 sufficient for such treating or preventing.

13. The method of claim 12 wherein the mode of administration is oral or parenteral.

14. An amino acid ester salt represented by a formula selected from the group consisting of:



and



wherein X is independently selected from the group consisting of

F, Cl, Br, and CF<sub>3</sub>;

5



A is N or CH;

R is H, CH<sub>3</sub>, or C<sub>2</sub>H<sub>5</sub>,

R' is H, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>,

AN<sup>-</sup> is an anion;

R'' is H, CH<sub>3</sub>, CH<sub>2</sub>OR''', CH(OR''')CH<sub>3</sub>; CH<sub>2</sub>SR''',



CH<sub>2</sub>COO<sup>-</sup> M<sup>+</sup>, CH<sub>2</sub>CH<sub>2</sub>COO<sup>-</sup> M<sup>+</sup>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>3</sub><sup>+</sup> AN<sup>-</sup>



$M^+$  is a metal cation; and

$R'''$  is H, phosphate ester, sulphate ester and proline ester.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/09242

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D405/14 A61K31/41

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 539 938 (SCHERING CORPORATION) 5 May 1993 see pages 14,15,24,25 and claims ---	1-14
P,Y	WO,A,95 17407 (SCHERING CORPORATION) 29 June 1995 see claims ---	1-14
P,Y	WO,A,95 19983 (JANSSEN PHARMACEUTICA N.V.) 27 July 1995 see claims -----	1-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

6 September 1996

Date of mailing of the international search report

13.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Chouly, J

## INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 96/ 09242

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark : Although claims 12, 13 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/09242

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-539938	05-05-93	AU-B- 665218	21-12-95
		AU-B- 2916992	07-06-93
		CA-A- 2122270	13-05-93
		CN-A- 1073944	07-07-93
		CZ-A- 9401027	15-03-95
		EP-A- 0610377	17-08-94
		FI-A- 941986	29-04-94
		HR-A- 921145	11-08-94
		HU-A- 70742	30-10-95
		JP-T- 7500605	19-01-95
		NO-A- 941589	23-06-94
		NZ-A- 244910	26-01-96
		SK-A- 48894	08-02-95
		WO-A- 9309114	13-05-93
		ZA-A- 9208342	29-04-93
-----			
WO-A-9517407	29-06-95	AU-B- 1512795	10-07-95
		NO-A- 962616	07-08-96
-----			
WO-A-9519983	27-07-95	AU-B- 1535595	08-08-95
		NO-A- 963073	23-07-96
-----			